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Purpose: The purpose of this study was to develop and preliminarily evaluate the reliability and validity
of the Symptom-Management Self-Efﬁcacy ScaleeBreast Cancer (SMSES-BC) related to chemotherapy.
Methods: The study included three stages. This paper presents the results of stage 2 and stage 3. In total,
34 items in the SMSES-BC were found during stage 1 from qualitative ﬁndings, a literature review, and
expert suggestions; the 34 items were used for the psychometric properties test. Test-retest reliability
and Cronbach a were assessed in the ﬁrst sample, which included 45 participants for the pilot test (stage
2). The second sample, which included 152 patients, was used to assess the construct validity and
concurrent validity (stage 3).
Results: The pilot test results revealed a test-retest reliability of .73 (p < .001) and Cronbach a coefﬁcient
of .96 for the total scale. Three factors (managing chemotherapy-related symptoms, acquiring problem
solving, and managing emotional and interpersonal disturbances) were identiﬁed from exploratory
factor analysis. Correlation coefﬁcient r was .40 (p < .001), which supported the association between
SMSES-BC and the General Self-Efﬁcacy Scale for concurrent validity.
Conclusions: The study results demonstrate acceptable reliability and validity for the SMSES-BC that was
developed for measuring symptom-management self-efﬁcacy related to chemotherapy for patients with
breast cancer. This study suggests further research to validate the construct of the SMSES-BC.
Copyright © 2015, Korean Society of Nursing Science. Published by Elsevier. All rights reserved.Introduction
Breast cancer is one of the most common cancers in the world.
Among all cancers affecting women in Taiwan, it ranks ﬁrst in terms
of prevalence and fourth in terms of mortality [1]. Chemotherapy is
the standard treatment and has improved the survival rate of breast
cancer patients [2,3]. Depending on the stage of diagnosis, the
overall survival rate of breast cancer varies from 27% to 100% [3].
However, complications from chemotherapy overwhelm the pa-
tient's overall quality of life [4,5], such as leukopenia, edema and
diarrhea [6], speciﬁcally the side effects of multiple chemotherapy
regimens on the patients progressive tumor [7]. As our under-
standing of cancer extended, the treatment of advanced breastrofessor, College of Nursing,
ciences, 365 Ming Te Road,
ciety of Nursing Science. Publishedcancer usually involves a combination of chemotherapy, hormone
therapy, and target therapy [8].
Chemotherapy treatment has shifted from inpatient to outpa-
tient care. Therefore, self-management is important for patients for
controling symptoms related to chemotherapy at home [9].
Nevertheless, patients face various challenges related to the com-
plications from chemotherapy because of the various symptom
etiologies [10]. For example, pain may be caused by the cancer, and
sleep disturbance may be caused by anxiety or the selected
chemotherapy agents, which impede patients' capacity to self-
manage the side effects and further obstruct the treatment effects.
Researchhas revealed that inperformingself-managementof side
effects, patients usually confront many difﬁculties, including acqui-
sition of accurate information and self-care skills if health pro-
fessionals are busy at the clinic and situations in which the
suggestions of health professionals are not suitable to the subject's
condition. As a result, patients have difﬁculty developing self-care
strategies [9,11,12].by Elsevier. All rights reserved.
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as a method for improving patient self-management behaviors
related to chemotherapy; however, the execution of these strate-
gies has not yet reached its potential [11,13]. In fact, the enhance-
ment of a patient's knowledge and skill to improve patient behavior
is limited. Patients may encounter various obstacles in conducting
self-management behavior [9,12]. Indeed, traditional patient edu-
cation may be insufﬁcient in improving the management of side
effects related to chemotherapy.
Many notions assert that belief is crucial for individual health
behavior [14e16]. Self-efﬁcacy is the belief in an individual's ability
to perform a speciﬁc task according to the speciﬁc components of
the health behaviors being performing [16,17]. Particularly, self-
efﬁcacy inﬂuences persistence and effort level for an individual to
overcome difﬁcult circumstances. Self-efﬁcacy is a potentially
modiﬁable variable; by itself, it can provide the basis for effective
interventions to improve health outcomes. Instruments have
addressed self-efﬁcacy among cancer patients but have focused on
either the global impact of the disease [18,19] or particular aspects
of a cancer diagnosis [20], breast cancer survivor [21], communi-
cation [22] or analgesic use [23]. The availability of a psychomet-
rically robust instrument that can explore the potential role of self-
efﬁcacy may enhance researchers' understanding of the patients'
capability beliefs and also the health outcomes of patients with
breast cancer who have received chemotherapy. Particularly, the
chemotherapy regimens keep changing as new chemotherapies
and biotherapies are being developed. Therefore, novel symptom
management assessment should be reﬂective of this trend. Our
study aimwas to develop and evaluate the reliability and validity of
the Symptom-Management Self-Efﬁcacy ScaleeBreast Cancer
(SMSES-BC) in relation to chemotherapy.Methods
The study was composed of three stages. Stage 1 focused on
item generation, consisting of a qualitative interview that included
17 patients with breast cancer to identify main behaviors and tasks
involved in the symptom management of chemotherapy. Stage 2
was a pilot test designed to evaluate the content validity and pre-
liminary reliability of the initial scale developed from Stage 1. Stage
3 involved exploratory factor analysis, evaluating the concurrent
validity of the SMSES-BC. This paper reports the results of stage 2
and stage 3. Approval to conduct the study was obtained from the
institutional ethics committees of the participating agencies. All
participants signed informed consent agreements.Pilot test (Stage 2)
Instrument development
A draft of the 33-item, self-administered SMSES-BC for patients
with breast cancer undergoing chemotherapy was developed from
an earlier qualitative study and literature review. This scale
included 3 items regarding communicating about chemotherapy-
related concerns, 14 items concerning the measurement of
chemotherapy-related symptoms, 7 items about managing
emotional and interpersonal disturbances, and 9 items regarding
acquiring relevant resources. Items in the scale were based on the
categories that emerged from interview ﬁndings and the literature
review to assess the main behaviors and tasks relevant to
symptom-management self-efﬁcacy.
In the SMSES-BC scale, there are 11-point responses for various
behaviors, ranging from 0 to 10, with 0 signifying not at all conﬁdent
and 10 signifying complete conﬁdence. A higher response score in-
dicates higher perceived symptom-management self-efﬁcacy.Six experts (2 oncology physicians, 3 oncology nursing experts,
and 1 professor specializing in self-efﬁcacy research) reviewed the
initial version of the scale for relevance and clarity. Agreement on
content validity ranged from .83 to 1.00; however, the experts
suggested that two items for measuring communication about
chemotherapy-related concerns be combined into one item. Addi-
tionally, these experts suggested that twomore items be added: one
item regarding managing chemotherapy-related symptoms and an
item regarding acquiring relevant resources. Minor changes were
made to the wording of some items according to panelist sugges-
tions. Finally, 34 items of the scale were used in the pilot study.
Sample
The sample for stage 2 of the pilot study included 45 women
(100%) from the oncology outpatient departments of two hospitals
in the southern and northern areas of Taiwan. Participants had a
breast cancer diagnosis that had received at least three courses of
chemotherapy, were older than 18 years, and were conscious and
able to sign the consent form. Participants' ages ranged from 30
years to 78 years old, with a mean age of 55.0 years (SD ¼ 11.0
years). Most patients were married (71.1%), lived with others
(84.4%), had an educational level of primary school or below
(42.2%), were either Buddhist (57.7%) or Taoist (22.2%), and were
not working (60.0%). Around 77.3% of the participants had a diag-
nosis of metastatic breast cancer.
Internal consistency
Internal reliability was tested using the Cronbach a coefﬁcient of
the scale and subscales. The initial Cronbach a for the entire scale
was .96. Cronbach a of each of the four initial subscales that were
developed for evaluating the main four constructs derived from the
Stage 1 interviews exceeded .70. The current results revealed a
recommended standard of above .70 [24].
Test-retest reliability
Stability was conﬁrmed by test-retest with the initial pilot
sample. The retest was performed approximately 2 weeks after the
ﬁrst completion of the scale. The current results of test-retest sta-
bility showed a signiﬁcant correlation between the initial score and
the retest score for all subscales (r¼ .40, p < .001 to r¼ .78, p < .001)
and the total scale (r ¼ .73, p < .001). The results supported good
test-retest reliability for the initial version of SMSES-BC [24].
Construct and concurrent validity (Stage 3)
Sample
The sample consisted of 152 outpatients with breast cancer
recruited fromtwo teachinghospitals in southernandnorthern areas
of Taiwan. The sampling frame and inclusion criterionmatchedwith
those of stage 2 (the pilot study). Participants included 152 women
(100%) diagnosed with breast cancer. Participants' ages ranged from
30years to78yearsold,withameanageof54.3years (SD¼9.9years).
Most participants were married (71.7%), lived with others (77.6%),
had an education level of primary school and below (24.3%), had a
religion (87.5%), and were not working (66.5%). Participants were
diagnosed breast cancer with a mean duration of 4.2 years (SD¼ 5.4
years). Around64.7% of the participants had a diagnosis ofmetastatic
breast cancer. All patients underwent the treatment with various
therapeutic agents included chemotherapy (65.2%), hormone ther-
apy (37.6%), and target therapy (24.9%).
Measures
In addition to the 34-item SMSES-BC, the General Self-Efﬁcacy
Scale (GSES) was used to establish concurrent validity with the
SMSES-BC. The GSES is a 10-item scale designed to evaluate the
S.-Y. Liang et al. / Asian Nursing Research 9 (2015) 312e317314individual's beliefs of theirability in facingvarious life challenges. The
GESE uses a 4-point Likert scale, ranging from 0 to 3, to assess pa-
tients' responses. The validity and reliability of GSES is well-
established [25e27]. The content validity index ranged from .75 to
1.00 [27], and the relevance and clarity were scored by six panelist
judges on a scale from 1 to 4; r for test-retest reliability ranged from
.75 to .94, and theCronbacha coefﬁcient ranged from .92 to .93 for the
Chinese version of GSES [25e27].
Item analysis
Item analysis of the original 34-item scalewas evaluatedwith the
critical ratio and item-to-total correlation coefﬁcient. The critical
ratio for each itemwas analyzed via t test, and its results ranged from
3.76 to 5.39 (t¼ 7.52e13.23, p< .001). The results revealed signiﬁcant
differences between the high-scoring group (with the highest 27.0%
of scores) and low-scoring group (with the lowest 27.0% of scores)
[28]. This ﬁnding supports the discriminatory power of the items in
the SMSES-BC. Additionally, all item-total correlations were greater
than .40, which is the standard for acceptability [29].
Results
Construct validity of SMSES-BC
The current study used exploratory principal component factor
analysis to explore the potential constructs in the preliminary set of
34 self-efﬁcacy items. Results of the Kaiser-Meyer-Olkin measure
for sampling adequacy was .93; additionally, Barlett's test ofTable 1 Components of Factors and factor loadings and Communalities in SMSES-BC (27 ite
Factor/Item
Factor 1
29. (MC) Managing hair loss
25. (MC) Managing peripheral problem of limbs
20. (MC) Preventing infection
23. (MC) Managing nail problem
17. (MC) Managing skin problem
22. (MC) Managing pain
27. (MC) Managing memory loss
Factor 2
1. (ME) Managing social activity disturbance
2. (ME) Managing emotional distress
6. (ME) Managing interpersonal stress
11. (ME) Seeking place for emotion
32. (AR) Obtaining support from surrounding people
30. (ME) Managing interpersonal isolation
Factor 3
15. (MC) Managing sleeping problem
3. (MC) Managing palpitation
8. (MC) Managing nausea and vomiting
16. (MC) Managing eating problem
10. (MC) Managing endocrine problem
5. (MC) Managing fatigue
34. (MC) Managing gastrointestinal problem
Factor 4
12. (CC) Actively talk with health professional about the side effects of chemothera
14. (CC) Actively talk with health professional about my side effects of chemothera
26. (CC) Actively talk with health professional about the management of side effect
13. (MC) Managing the problems related to oral mucosa
Factor 5
24. (AR) Obtaining support from social group
28. (AR) Obtaining internet resources to manage the problems related to chemothe
31. (AR) Managing the work problems related to chemotherapy
Eigenvalue
Percentage of variance explained
Cumulative percentage
Note. AR ¼ acquiring relevant resources; CC ¼ communicating about chemotherapy relat
ME ¼ managing emotional and interpersonal disturbance; SMSES-BC ¼ Symptom-Manasphericity for appropriate assumptions was signiﬁcant
(c2¼ 3909.01, df¼ 496, p¼ .001), indicating that the factor analysis
was ﬁt.
In this study, we used the orthogonal varimax rotation for the
original principal component factor analysis. The results presented
ﬁve factors with an eigenvalue of 1.00 or greater. These ﬁve factors
were linked to 67.1% of the variance. All items were loaded onto at
least one factor at the .40 level or above. Communalities for all
items exceeded .50.
To determine and clarify the number of items and factors to
keep, several statistical processes and conceptual bases were
considered [30]. Although six items that were originally concep-
tualized as measuring “acquiring and utilizing relevant resources”
loaded onto four separate factors, these items could not be differ-
entiated conceptually. Therefore, they were removed from the
preliminary SMSES-BC. Furthermore, one item initially conceptu-
alized as assessing the construct of managing emotional and
interpersonal disturbance loaded onto factor 3. This item did not
suit conceptually with the other items loading onto factor 3, which
were used to assess the concept of managing chemotherapy-
related symptoms. Therefore, this item was also removed. Of the
initial 34 items, 7 items were excluded, and 27 items remained.
A ﬁnal factor analysis was then completed on the 27 remaining
items to approve the recommended factor structure. The results of
the factor analysis extracted ﬁve factors with eigenvalues over 1.
These ﬁve factors contributed to 70.2% of the variance (see Table 1).
The results of the communalities in the factor analysis ranged be-
tween .62 and .78 (see Table 1). Items greater than .45 (cut-off),ms) (N ¼ 152).
Factor/Factor loading h2
1 2 3 4 5
0.79 e 0.17 e 0.27 0.73
0.67 0.32 0.22 0.33 0.15 0.73
0.66 0.28 0.32 0.26 0.17 0.70
0.61 0.37 0.25 0.42 0.16 0.77
0.60 0.23 0.31 0.48 e 0.74
0.49 0.39 0.43 0.30 e 0.67
0.49 e 0.47 0.10 0.39 0.62
0.21 0.71 0.15 0.11 0.31 0.68
0.18 0.70 0.44 0.16 e 0.74
0.19 0.67 0.34 0.22 0.32 0.75
0.24 0.64 0.20 0.28 0.23 0.64
0.33 0.61 0.14 0.47 0.15 0.74
0.55 0.45 0.17 0.24 0.31 0.69
0.14 0.17 0.77 0.23 0.17 0.72
0.19 0.27 0.68 0.13 0.19 0.62
0.35 0.25 0.67 e 0.13 0.65
0.17 0.43 0.64 0.35 e 0.75
0.42 e 0.59 0.32 e 0.64
0.13 0.58 0.54 0.22 0.15 0.71
0.45 0.44 0.46 0.40 e 0.77
py before treatment 0.17 0.19 0.13 0.79 0.27 0.78
py after treatment 0.11 0.17 0.22 0.79 0.24 0.76
s of chemotherapy 0.30 0.24 0.27 0.61 0.30 0.68
0.36 0.36 0.21 0.60 0.14 0.68
0.14 0.16 0.14 0.29 0.76 0.72
rapy 0.19 0.34 e 0.18 0.68 0.65
0.26 0.19 0.36 0.23 0.60 0.64
4.29 4.25 4.24 3.75 2.42
15.9 15.8 15.7 13.9 9.0
15.9 31.7 47.4 61.2 70.2
ed concerns; h2 ¼ communality; MC ¼managing chemotherapy related symptoms;
gement Self-Efﬁcacy Scale-Breast Cancer. Underlined values mean factor loadings.
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on the factor with the ﬁnest conceptual properties of the original
constructs [28,30].
The results of the ﬁnal factor analysis showed that items origi-
nally developed to assess the concept of managing chemotherapy-
related symptoms continued to load separately on two different
factors (7 items loaded on factor 1 and the other 7 items loaded on
factor 3). These two factors were combined to create one scale
assessing managing chemotherapy-related symptoms. Moreover,
the association between these two factors indicated intercorrelations
(Pearson's r ¼ .79, p < .001), suggesting a conceptual alliance.
Except for item 32, all items loading on factor 2 echoed the
dimension of managing emotional and interpersonal disturbance.
Item 32was initially developed to evaluate the concept of acquiring
and utilizing relevant resources (AR). This item loaded on both
managing emotional and interpersonal disturbance (factor 2)
and communicating about chemotherapy-related concerns
(factor 4), with factor loading over .45. Therefore, item 32 was kept
as part of communicating about chemotherapy-related concerns
(factor 4).
Moreover, except for item 13, all items loading on factor 4 were
initially developed to evaluate the concept of communicating about
chemotherapy-related concerns. Item 13 was initially developed to
evaluate the concepts of managing chemotherapy-related symp-
toms, and its original conception was to measure self-management
of the oral mucosa because such management was an important
issue in chemotherapy. Therefore, item 13 was kept as part of
managing chemotherapy-related symptoms. Three items that were
initially developed to evaluate the concept of acquiring relevant
resource loaded above .45 on factor 5. Finally, factor 4 and factor 5
were combined to create one scale, which was renamed acquiring
problem-solving. These factors were integrated because of the
small number of items of the two separate factors and because
items that initially measured AR crossloaded on factor 4, such asTable 2 Names of Subscales and Item Descriptions for Revised SMSES-BC.
Item
Subscale 1 (7 items): Acquiring problem-solving (AP)
9. Actively talk with health professional about the side effects of chemotherapy b
11. Actively talk with health professional about my side effects of chemotherapy a
18. Obtaining support from social group (e.g., peer group, church member)
20. Actively talk with health professional about the management of side effects of
22. Obtaining internet resources to manage the problems related to chemotherapy
25. Managing the work problems related to chemotherapy (e.g., asking for sick lea
26. Obtaining support from surrounding people (e.g., health professional, family, fr
Subscale 2 (15 items): Managing chemotherapy-related symptoms (MC)
3. Managing palpitations (e.g., tachycardia)
4. Managing fatigue (e.g., tiredness, weakness)
6. Managing nausea and vomiting
7. Managing endocrine problems (e.g., night sweat, ﬂush)
10. Managing the problems related to oral mucosa (e.g., mucositis, cheilosis)
12. Managing sleeping problems (e.g., insomnia, light sleeping)
13. Managing eating problems (e.g., difﬁculty in swallowing, parageusia, poor appe
14. Managing skin problems (e.g., darkening, decortication, skin rash, itching)
15. Preventing infection (e.g., anemia, blood cells decreasing)
16. Managing pain (e.g., bone pain, sore muscles, spasm)
17. Managing nail problems (e.g., darkening, deformation, burst)
19. Managing peripheral problems of limbs (e.g., numbness, rigid)
21. Managing memory problems (e.g., short memory, forgetful)
23. Managing hair loss
27. Managing gastrointestinal problems (e.g., distention, constipation, diarrhea)
Subscale 3 (5 items): Managing emotional and interpersonal disturbance (ME)
1. Managing social activity disruptions (e.g., stopping gathering, stopping gossip)
2. Managing emotional distress (e.g., feeling down, powerless, worry, fear)
5. Managing interpersonal stress (e.g., stress from people paying attention)
8. Seeking place for emotion (e.g., religion, painting, patchwork, book)
24. Managing interpersonal isolation
Note. SMSES-BC¼ Symptom-Management Self-Efﬁcacy ScaleeBreast Cancer.item 32. Nevertheless, communalities of all items that loaded on
factor 4 and factor 5 were above .6, suggesting that these items
revealed communal factor variance [29]. Additionally, the associa-
tion between these two factors indicated intercorrelation (Pear-
son's r ¼ .63, p < .001), further indicating that these two factors
were conceptually linked.
The names of the subscales and associated items that were
included in the revised 27 items of the SMSES-BC are presented in
Table 2. The revised 27 items were assessed using conﬁrmatory
factor analysis. The standardized factor loading for each item
ranged between .58 and .80 for factor 1, between .59 and .84 for
factor 2, and between .71 and .84 for factor 3. The results indicated
that the latent variable can be measured by the items [31].
Internal consistency of the revised 27-item SMSES-BC
Internal consistency was evaluated for the 27-item scale and
subscales of SMSES-BC (Table 3). The internal reliability for the total
scale was .96. The Cronbach a for all subscales ranged from .88 to
.95. Moreover, the item-total correlation of the total scale and each
subscale was greater than .40.
Concurrent validity of the revised 27-item SMSES-BC
The SMSES-BC signiﬁcantly correlated with the GSES (r ¼ .40,
p < .001). Additionally, all subscales of the SMSES-BC signiﬁcantly
and positively correlated with the GSES (r ¼ .37e.40, p < .001)
(Table 4).
Discussion
The purpose of this study was to develop and preliminarily
evaluate a scale for measuring symptom-management self-efﬁcacy






Table 3 Reliability of Revised SMSES-BC (N ¼ 152).




1 7 .88 .57e.73
2 15 .95 .58e.81
3 5 .88 .65e.78
Total scale 27 .96 .56e.81
Note. SMSES-BC¼ Symptom-Management Self-Efﬁcacy ScaleeBreast Cancer.
Table 4 Relationships between Total Scale and Subscales of SMSES-BC and GSES
(N ¼ 152).
Subscales No. of items Pearson's r p




3. Managing emotional and
interpersonal disturbance
5 .40 .001
Total scale 27 .40 .001
Note. GSES ¼ General Self-Efﬁcacy Scale; SMSES-BC¼ Symptom-Management Self-
Efﬁcacy ScaleeBreast Cancer.
S.-Y. Liang et al. / Asian Nursing Research 9 (2015) 312e317316ﬁnal SMSES-BC is a 27-item self-administered scale. The results of
Cronbach a and test-retest reliability showed that the SMSES-BC is
a scale with internal consistency, yielding stable scores if measured
repeatedly [29,30,32,33].
The results of construct and concurrent validity for the pre-
liminary evaluation of the SMSES-BC also demonstrated that the
scale was acceptable. For construct validity, results of the factor
analysis revealed that the scale was naturally multidimensional.
Three factors emerged from the factor analysis, including acquiring
problem-solving, managing chemotherapy-related symptoms, and
managing emotional and interpersonal disturbances. Researchers
have suggested that for an exploratory principal component factor
analysis, a sample size of 150e200 and a factor loading of at least
.45 are required [28]. This study was conducted in accordance with
these criteria, and the assumptions for a factor analysis also ﬁt the
data. The current results supported the appropriate construct val-
idity. Nevertheless, concurrent validity was demonstrated by sig-
niﬁcant correlations between the SMSES-BC and GSES. These
relationships are robust. GSES is the “gold standard” of criterion-
referenced assessment for many studies related to the develop-
ment of the self-efﬁcacy scales [34,35]. Essentially, the current re-
sults supported the criterion validity of the SMSES-BC.
The SMSES-BC can be used to identify speciﬁc behavior tasks
performed by patients in managing individual symptoms related to
chemotherapy. Particularly this scale is designed speciﬁcally to
assess the symptom management required during chemotherapy.
For clinical practice, the message emerged from this scale may
provide healthcare providers with an understanding of the chal-
lenges that individual patients face and encourage a valuable dis-
cussion regarding symptom management. Furthermore, this scale
is particularly important for clinicians to assess the extent to which
a patient reports lower levels of conﬁdence in being able to perform
these self-management behaviors, so that such difﬁculties can be
the target of appropriate health professional intervention. For
research, the scale provides an effective measurement for under-
standing an individual's belief in his or her ability to manage
symptoms related to chemotherapy and for predicting patient self-
care behaviors [16].
The advantage of the SMSES-BC is that the scale originated from
patients with breast cancer. This scale was developed and tested by
means of patients with breast cancer who had received chemo-
therapy. Patients were therefore more likely to provide accuratemeasurements of their beliefs in competencies involved in man-
aging symptoms related to chemotherapy. Therefore, this scale has
inherent content validity. Furthermore, the items in this scale
reﬂect multiple aspects of tasks, behaviors, and situations associ-
ated with symptom-management for chemotherapy identiﬁed by
patients. This scale provides a holistic perspective in assessing an
individual's beliefs in relation to self-management of chemo-
therapy symptoms.
The preliminary development of the SMSES-BC is designed for
use among a wide range of patients with breast cancer, varying in
age, stage, and treatment modalities. This study suggests further
research to validate the construct of the SMSES-BC. The develop-
ment of SMSES-BC is limited by the preliminary nature of the
analysis. As such, more research utilizing conﬁrmatory factor
analysis, for example, structural equationmodeling and convergent
and discriminant validity, is needed to further investigate the po-
tential importance symptom-management self-efﬁcacy.Conclusion
This study provides initial evidence of the reliability and validity
of the SMSES-BC. The reliability evaluations acquired in this 27-
item scale indicated appropriate internal consistency. Concurrent
validity of the SMSES-BC was also supported. Further validation is
suggested; however, based on the results presented from the pre-
sent study, the scale is suitable for measuring a variable that may be
an important factor in achieving andmaintaining self-management
of symptoms caused by chemotherapy in patients with breast
cancer. The SMSES-BC can help professionals assess the patients'
capability beliefs in terms of self-efﬁcacy in relation to self-
management of chemotherapy.Conﬂicts of interest
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